ResMed Inc. (RMD) reported results for its quarter ended June 30, 2018. ResMed's revenue increased 12% to $623.6 million (up 10% on a constant currency basis), net income increased by 8% and non-GAAP net income surged 24% compared to the same period of the prior year. The company closed out the year with strong performance across all aspects of its business, from solid top-line revenue growth - driven by geographically balanced results across its entire portfolio of offerings - to continued improvements in operating leverage, which has resulted in double-digit bottom-line growth.
http://crweworld.com/article/news-p...ts-for-the-fourth-quarter-of-fiscal-year-2018
ResMed in Numbers - Highlights from its Q4 of FY2018
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.39 |
Change
0.390(1.05%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.30 | $37.39 | $37.07 | $9.449M | 253.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $37.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.39 | 2573 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
